Knights of Columbus Asset Advisors LLC Has $120,000 Stock Holdings in Fate Therapeutics, Inc. (NASDAQ:FATE)

Knights of Columbus Asset Advisors LLC boosted its holdings in shares of Fate Therapeutics, Inc. (NASDAQ:FATE) by 100.0% in the fourth quarter, Holdings Channel reports. The firm owned 32,184 shares of the biopharmaceutical company’s stock after purchasing an additional 16,092 shares during the quarter. Knights of Columbus Asset Advisors LLC’s holdings in Fate Therapeutics were worth $120,000 at the end of the most recent reporting period.

A number of other institutional investors also recently added to or reduced their stakes in FATE. Envestnet Asset Management Inc. lifted its position in shares of Fate Therapeutics by 20.0% during the 1st quarter. Envestnet Asset Management Inc. now owns 8,734 shares of the biopharmaceutical company’s stock worth $339,000 after buying an additional 1,457 shares during the period. Raymond James & Associates lifted its holdings in shares of Fate Therapeutics by 42.6% during the first quarter. Raymond James & Associates now owns 29,436 shares of the biopharmaceutical company’s stock valued at $1,141,000 after acquiring an additional 8,790 shares during the period. HighTower Advisors LLC boosted its stake in shares of Fate Therapeutics by 5.9% in the 1st quarter. HighTower Advisors LLC now owns 18,361 shares of the biopharmaceutical company’s stock valued at $714,000 after purchasing an additional 1,016 shares in the last quarter. Private Advisor Group LLC grew its holdings in shares of Fate Therapeutics by 25.7% in the 1st quarter. Private Advisor Group LLC now owns 9,481 shares of the biopharmaceutical company’s stock worth $367,000 after purchasing an additional 1,938 shares during the last quarter. Finally, PNC Financial Services Group Inc. lifted its holdings in Fate Therapeutics by 17.1% during the 1st quarter. PNC Financial Services Group Inc. now owns 6,737 shares of the biopharmaceutical company’s stock valued at $260,000 after purchasing an additional 986 shares during the last quarter. 97.54% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages have weighed in on FATE. Needham & Company LLC reaffirmed a “hold” rating on shares of Fate Therapeutics in a research note on Thursday, April 11th. HC Wainwright restated a “neutral” rating and issued a $7.00 target price on shares of Fate Therapeutics in a research note on Tuesday, March 19th. Morgan Stanley upped their price target on shares of Fate Therapeutics from $3.00 to $7.00 and gave the stock an “equal weight” rating in a research report on Tuesday, February 27th. BMO Capital Markets raised their price objective on shares of Fate Therapeutics from $6.00 to $7.00 and gave the company a “market perform” rating in a research report on Tuesday, February 27th. Finally, Wedbush increased their price target on shares of Fate Therapeutics from $3.00 to $7.00 and gave the company a “neutral” rating in a research note on Tuesday, February 27th. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $6.73.

Fate Therapeutics Price Performance

Shares of NASDAQ FATE opened at $4.79 on Monday. Fate Therapeutics, Inc. has a fifty-two week low of $1.63 and a fifty-two week high of $8.83. The firm has a market capitalization of $545.20 million, a P/E ratio of -2.92 and a beta of 1.66. The company’s 50 day simple moving average is $6.92 and its 200 day simple moving average is $4.52.

Fate Therapeutics (NASDAQ:FATE) last issued its earnings results on Monday, February 26th. The biopharmaceutical company reported ($0.45) EPS for the quarter, beating the consensus estimate of ($0.57) by $0.12. The firm had revenue of $1.68 million during the quarter, compared to the consensus estimate of $0.85 million. Fate Therapeutics had a negative net margin of 253.30% and a negative return on equity of 38.17%. During the same quarter in the prior year, the firm earned ($0.58) earnings per share. Sell-side analysts expect that Fate Therapeutics, Inc. will post -1.94 EPS for the current fiscal year.

About Fate Therapeutics

Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders.